Progyny, Inc. (NASDAQ:PGNY) CFO Mark S. Livingston Sells 11,165 Shares

Progyny, Inc. (NASDAQ:PGNY) CFO Mark S. Livingston sold 11,165 shares of the company’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $37.62, for a total transaction of $420,027.30. Following the completion of the sale, the chief financial officer now directly owns 50,119 shares in the company, valued at $1,885,476.78. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Progyny Stock Performance

Progyny stock opened at $35.75 on Thursday. The company has a 50-day simple moving average of $37.81 and a 200-day simple moving average of $35.65. The firm has a market capitalization of $3.45 billion, a P/E ratio of 57.66, a P/E/G ratio of 1.47 and a beta of 1.48. Progyny, Inc. has a one year low of $29.44 and a one year high of $44.95.

Progyny (NASDAQ:PGNY) last released its quarterly earnings results on Tuesday, February 27th. The company reported $0.13 EPS for the quarter, topping the consensus estimate of $0.09 by $0.04. The business had revenue of $269.94 million during the quarter, compared to analyst estimates of $274.08 million. Progyny had a net margin of 5.70% and a return on equity of 12.64%. The company’s quarterly revenue was up 26.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.03 earnings per share. As a group, sell-side analysts forecast that Progyny, Inc. will post 0.7 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on PGNY. KeyCorp cut their price target on shares of Progyny from $45.00 to $43.00 and set an “overweight” rating on the stock in a report on Wednesday, February 28th. SVB Leerink began coverage on shares of Progyny in a report on Monday, February 26th. They issued an “outperform” rating and a $49.00 price target on the stock. Barclays began coverage on shares of Progyny in a report on Wednesday, January 3rd. They issued an “overweight” rating and a $48.00 price target on the stock. Leerink Partnrs reaffirmed an “outperform” rating on shares of Progyny in a report on Monday, February 26th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $48.00 target price on shares of Progyny in a report on Wednesday, February 28th. Ten investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $48.30.

Hedge Funds Weigh In On Progyny

Several institutional investors have recently modified their holdings of the company. Vanguard Group Inc. grew its position in shares of Progyny by 1.4% during the fourth quarter. Vanguard Group Inc. now owns 8,270,153 shares of the company’s stock worth $307,484,000 after acquiring an additional 112,549 shares during the last quarter. Wellington Management Group LLP bought a new position in Progyny in the 4th quarter valued at about $14,608,000. Congress Asset Management Co. MA grew its position in Progyny by 13.1% in the 4th quarter. Congress Asset Management Co. MA now owns 902,909 shares of the company’s stock valued at $33,570,000 after buying an additional 104,465 shares in the last quarter. Cim LLC bought a new position in Progyny in the 4th quarter valued at about $356,000. Finally, Price T Rowe Associates Inc. MD grew its position in Progyny by 6.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 51,965 shares of the company’s stock valued at $1,933,000 after buying an additional 3,189 shares in the last quarter. Institutional investors own 94.93% of the company’s stock.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.